SG11201808559PA - Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide - Google Patents

Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

Info

Publication number
SG11201808559PA
SG11201808559PA SG11201808559PA SG11201808559PA SG11201808559PA SG 11201808559P A SG11201808559P A SG 11201808559PA SG 11201808559P A SG11201808559P A SG 11201808559PA SG 11201808559P A SG11201808559P A SG 11201808559PA SG 11201808559P A SG11201808559P A SG 11201808559PA
Authority
SG
Singapore
Prior art keywords
hydroxypyrrolidine
pyrazolo
difluorophenyl
pyrrolidin
pyrimidin
Prior art date
Application number
SG11201808559PA
Inventor
Mark Reynolds
Steven A Smith
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58549282&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201808559P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of SG11201808559PA publication Critical patent/SG11201808559PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
SG11201808559PA 2016-04-04 2017-04-04 Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide SG11201808559PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662318041P 2016-04-04 2016-04-04
US201662323452P 2016-04-15 2016-04-15
US201662329561P 2016-04-29 2016-04-29
PCT/US2017/025939 WO2017176751A1 (en) 2016-04-04 2017-04-04 Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

Publications (1)

Publication Number Publication Date
SG11201808559PA true SG11201808559PA (en) 2018-10-30

Family

ID=58549282

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808559PA SG11201808559PA (en) 2016-04-04 2017-04-04 Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

Country Status (28)

Country Link
US (3) US10137127B2 (en)
EP (1) EP3439662A1 (en)
JP (1) JP7061602B2 (en)
KR (1) KR102400423B1 (en)
CN (1) CN109414442B (en)
AU (1) AU2017246554B2 (en)
BR (1) BR112018070304A2 (en)
CA (1) CA3019671C (en)
CL (2) CL2018002806A1 (en)
CO (1) CO2018010761A2 (en)
CR (1) CR20180501A (en)
CU (1) CU20180125A7 (en)
DO (1) DOP2018000214A (en)
EC (1) ECSP18083443A (en)
GE (1) GEP20227339B (en)
IL (2) IL304018A (en)
MA (1) MA44610A (en)
MX (1) MX2018012163A (en)
NI (1) NI201800102A (en)
PE (1) PE20181888A1 (en)
PH (1) PH12018502124A1 (en)
RU (1) RU2751767C2 (en)
SA (1) SA518400168B1 (en)
SG (1) SG11201808559PA (en)
TN (1) TN2018000335A1 (en)
TW (1) TWI746537B (en)
UA (1) UA125026C2 (en)
WO (1) WO2017176751A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2350075B1 (en) 2008-09-22 2014-03-05 Array Biopharma, Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
PT2350071E (en) 2008-10-22 2014-04-11 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
BR122019024201B1 (en) 2010-05-20 2021-08-03 Array Biopharma Inc MACROCYCLIC COMPOUND AS TRK KINASE INHIBITORS, ITS USE, AND PHARMACEUTICAL COMPOSITION
NZ731909A (en) 2014-11-16 2023-11-24 Array Biopharma Inc Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
CA3003153A1 (en) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
CR20180501A (en) 2016-04-04 2019-04-05 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
PT3458456T (en) 2016-05-18 2020-12-07 Array Biopharma Inc Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide
JOP20190092A1 (en) 2016-10-26 2019-04-25 Array Biopharma Inc PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
US11406564B2 (en) * 2017-05-05 2022-08-09 Hoffmann-La Roche Inc. Drug preparation kit and process of preparing a drug
WO2019120194A1 (en) * 2017-12-22 2019-06-27 深圳市塔吉瑞生物医药有限公司 Substituted pyrazolo[1,5-a]pyrimidine compound and pharmaceutical composition and use thereof
AU2019205279A1 (en) * 2018-01-08 2020-07-30 Susavion Biosciences, Inc. Compositions and methods of treating cancer with glycomimetic peptides
CN111848622A (en) 2018-01-23 2020-10-30 深圳市塔吉瑞生物医药有限公司 Macrocyclic compounds of the substituted pyrazolo [1,5-a ] pyrimidines
KR20210078500A (en) * 2018-10-17 2021-06-28 닛뽕 케미파 가부시키가이샤 Treatment or prevention of nocturia
CN110698484B (en) * 2019-06-05 2021-11-05 陕西理工大学 Pyrazolo [1,5-a ] pyrimidine-containing derivative, pharmaceutical composition and application
CN111138437B (en) * 2019-12-04 2021-03-05 杭州华东医药集团新药研究院有限公司 Substituted pyrazolo [1,5-a ] pyrimidine amino acid derivatives and uses thereof

Family Cites Families (281)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017286A (en) 1909-03-01 1912-02-13 Du Pont Powder Co Apparatus for treating explosive powder.
US1000578A (en) 1910-01-12 1911-08-15 Robert T Burdette Power-driven post-hole excavator.
US1001160A (en) 1910-04-05 1911-08-22 Paul A Otto Aerodrome.
US1004709A (en) 1910-05-20 1911-10-03 Albert E Yerkes Spraying device.
US1004599A (en) 1910-06-14 1911-10-03 C F Splitdorf Armature for electric generators.
US1013712A (en) 1911-06-03 1912-01-02 Alfred D Williams Tie and rail-fastener.
NZ234143A (en) 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
DE69432193T2 (en) 1993-11-30 2004-01-15 Searle & Co Substituted pyrazolyl-benzenesulfonamides and their use as cyclooxygenase II inhibitors
US5430021A (en) 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
CA2206201A1 (en) 1996-05-29 1997-11-29 Yoshiaki Isobe Pyrazole derivatives and their pharmaceutical use
JP3898296B2 (en) 1996-08-28 2007-03-28 ポーラ化成工業株式会社 Pyrrolopyrazolopyrimidine compounds and pharmaceuticals containing the same as active ingredients
ATE283270T1 (en) 1997-04-25 2004-12-15 Takeda Chemical Industries Ltd CONDENSED PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND USE
IL144025A (en) 1999-01-21 2004-05-12 Bristol Myers Squibb Co RAS-FARNESYL TRANSFERASE INHIBITOR COMPLEX CONTAINING A 1,4-BENZODIAZEPINE DERIVATIVE AND A beta-CYCLODEXTRIN DERIVATIVE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6534085B1 (en) 1999-09-23 2003-03-18 Bioresponse L.L.C. Phytochemicals for promoting weight loss
DE60140252D1 (en) 2000-06-22 2009-12-03 Genentech Inc AGONISTIC MONOCLONAL ANTIBODIES AGAINST TRKC
GB0028575D0 (en) 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
US20040067999A1 (en) 2000-12-22 2004-04-08 Block Michael Howard Carbazole derivatives and their use as neuropeptide y5 receptor ligands
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
JP2004535370A (en) * 2001-03-05 2004-11-25 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Liquid pharmaceutical composition with masked taste
CA2448956C (en) 2001-05-30 2017-10-03 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
US20030199525A1 (en) 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
AU2003227437A1 (en) 2002-04-23 2003-11-10 Shionogi And Co., Ltd. PYRAZOLO(1,5-a)PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
US7449488B2 (en) 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
ITMI20021620A1 (en) 2002-07-23 2004-01-23 Novuspharma Spa ANTI-TUMORAL ACTIVITY COMPOUND
JP4024624B2 (en) 2002-08-26 2007-12-19 富士通株式会社 Semiconductor device manufacturing method and manufacturing apparatus
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
EP1537116B1 (en) 2002-09-04 2010-06-02 Schering Corporation Pyrazolopyrimidines suitable for the treatment of cancer diseases
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004052315A2 (en) 2002-12-11 2004-06-24 Merck & Co., Inc. Tyrosine kinase inhibitors
US7262199B2 (en) 2002-12-11 2007-08-28 Merck & Co., Inc. Tyrosine kinase inhibitors
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
DE602004021472D1 (en) 2003-02-20 2009-07-23 Smithkline Beecham Corp Pyrimiidinverbindungen
US20070037150A1 (en) 2003-02-21 2007-02-15 The Johns Hopkins University Tyrosine kinome
JP2004277337A (en) 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE
EP1608652A1 (en) 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JP2006522749A (en) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ Pharmaceutical use of substituted pyrazolo [1,5-a] pyrimidines
US20060094699A1 (en) 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
WO2004089415A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
CA2523508A1 (en) 2003-04-28 2004-11-11 Galpharma Co., Ltd. Galectin 9-inducing factors
JO2785B1 (en) 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
JP2005008581A (en) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd NEW PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME AND APPLICATION THEREOF
EA009517B1 (en) 2003-06-27 2008-02-28 Байер Кропсайенс Аг Pyrazolopyrimidines
TWI503328B (en) 2003-07-15 2015-10-11 Amgen Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US7169918B2 (en) 2003-10-27 2007-01-30 Genelabs Technologies, Inc. Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
CA2546673A1 (en) 2003-11-28 2005-06-09 Novartis Ag Diaryl urea derivatives in the treatment of protein kinase dependent diseases
CA2549869C (en) 2003-12-18 2015-05-05 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
SI1696920T1 (en) 2003-12-19 2015-02-27 Plexxikon Inc. Compounds and methods for development of ret modulators
WO2005068424A1 (en) 2004-01-20 2005-07-28 Cell Therapeutics Europe S.R.L. Indolinone derivatives as receptor tyrosine kinase ihibitors
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
WO2005099363A2 (en) 2004-03-26 2005-10-27 Whitehead Institute For Biomedical Research Methods of diagnosing, preventing and treating cancer metastasis
CN1938311A (en) 2004-03-30 2007-03-28 因特蒙公司 Macrocyclic compounds as inhibitors of viral replication
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
PE20060664A1 (en) 2004-09-15 2006-08-04 Novartis Ag BICYCLE AMIDAS AS KINASE INHIBITORS
ZA200704476B (en) 2004-11-04 2008-09-25 Vertex Pharma Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
JO3088B1 (en) 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv Macrocyclic Quinazoline derivatives and their use as MTKI
DE102005003687A1 (en) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunodiagnostic determination of neurotensin in mammal blood, comprises injecting immune active N-terminal mammal proneurotensin in to the serum- or plasma- sample
ATE473975T1 (en) 2005-02-16 2010-07-15 Astrazeneca Ab CHEMICAL COMPOUNDS
CN101119996A (en) 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 Chemical compouns
JP4971300B2 (en) 2005-03-21 2012-07-11 イーライ リリー アンド カンパニー Imidazopyridazine compounds
JP2008540335A (en) 2005-04-27 2008-11-20 アストラゼネカ・アクチエボラーグ Use of pyrazolyl pyrimidine derivatives in the treatment of pain
NZ564317A (en) 2005-05-16 2011-01-28 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
CN100406650C (en) 2005-06-05 2008-07-30 徐斌 Modular comb type expansion joint installation of girder capable of resisting super displacement
ITRM20050290A1 (en) 2005-06-07 2006-12-08 Lay Line Genomics Spa USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS.
PE20070100A1 (en) 2005-06-22 2007-03-10 Plexxikon Inc PIRROLO [2,3-b] PYRIDINE DERIVATIVES AS KINE MODULATORS
US20070025540A1 (en) 2005-07-07 2007-02-01 Roger Travis Call center routing based on talkativeness
MX2008001166A (en) 2005-07-25 2008-03-18 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication.
WO2007013673A1 (en) 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
JP2009503071A (en) 2005-08-03 2009-01-29 イーストマン ケミカル カンパニー Tocopheryl polyethylene glycol succinate powder and method for producing the same
US20070191306A1 (en) 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
CA2619365A1 (en) 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
AU2006284096B2 (en) 2005-08-25 2012-03-29 Avro Life Sciences, Inc. Polymer conjugates of K-252a and derivatives thereof
DE102005042742A1 (en) 2005-09-02 2007-03-08 Schering Ag Substituted imidazo [1,2b] pyridazines as kinase inhibitors, their production and use as pharmaceuticals
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
CA2627623C (en) 2005-10-06 2014-04-22 Schering Corporation Methods for inhibiting protein kinases
TW200745128A (en) 2005-10-06 2007-12-16 Schering Corp Pyrazolopyrimidines as protein kinase inhibitors
JP5030961B2 (en) 2005-10-11 2012-09-19 サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク Compounds and kits for detection and quantification of cellular apoptosis
ES2356776T3 (en) 2005-10-11 2011-04-13 Intermune, Inc. COMPOUNDS AND METHODS TO INHIBIT THE REPLICATION OF THE HEPATITIS VIRUS.
ATE517874T1 (en) 2005-10-21 2011-08-15 Exelixis Inc PYRIMIDINONES AS MODULATORS OF CASEINKINASE II (CK2)
WO2007057399A2 (en) 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
GB0524436D0 (en) 2005-11-30 2006-01-11 Novartis Ag Organic compounds
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
US8399442B2 (en) 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
WO2007084815A2 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica, N.V. Substituted thienopyrimidine kinase inhibitors
EP1978958A4 (en) 2006-01-24 2009-12-02 Merck & Co Inc Ret tyrosine kinase inhibition
KR100846988B1 (en) 2006-03-06 2008-07-16 제일약품주식회사 Novel thienopyrimidine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
CA2645137A1 (en) 2006-03-07 2007-09-13 James F. Blake Heterobicyclic pyrazole compounds and methods of use
ZA200808966B (en) 2006-03-27 2010-03-31 Nerviano Medical Sciences Srl Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors
GB0606805D0 (en) 2006-04-04 2006-05-17 Novartis Ag Organic compounds
CL2007001165A1 (en) 2006-04-26 2008-01-25 Hoffmann La Roche 2- (1h-indazol-4-yl) -6- (4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin-4-yl-thieno [3,2-d] pyrimidine; preparation procedure; pharmaceutical composition; process of preparing said composition; pharmaceutical kit; and use to treat diseases such as cancer, immune disorders and cardiovascular diseases.
RU2448708C3 (en) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. ANTI-TUMOR MEANS AGAINST THYROID CANCER CANCER
US7389632B2 (en) 2006-06-10 2008-06-24 Uhlmann Pac-Systeme Gmbh & Co. Kg Apparatus for distributing small objects in a fill station
EP1873157A1 (en) 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
TW201345908A (en) 2006-07-05 2013-11-16 Mitsubishi Tanabe Pharma Corp A pyrazolo [1,5-a] pyrimidine compound
JPWO2008016131A1 (en) 2006-08-04 2009-12-24 武田薬品工業株式会社 Fused heterocyclic compounds
CL2007002261A1 (en) 2006-08-04 2008-05-02 Takeda Pharmaceutical COMPOUNDS DERIVED FROM IMIDAZO [1,2-B] PIRIDAZINA, QUINASA INHIBITORS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OR PREVENTION OF CANCER.
US7531539B2 (en) 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
AU2007292924A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
US20110195072A1 (en) 2006-09-12 2011-08-11 Anne Boulay Non-neuroendocrine cancer therapy
ATE502943T1 (en) 2006-09-29 2011-04-15 Novartis Ag PYRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS
US20100041662A1 (en) 2006-10-30 2010-02-18 Sandrine Ferrand Heterocyclic compounds as antiinflammatory agents
MY146474A (en) 2006-11-06 2012-08-15 Supergen Inc Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
PE20121126A1 (en) 2006-12-21 2012-08-24 Plexxikon Inc PIRROLO [2,3-B] PYRIDINES COMPOUNDS AS KINASE MODULATORS
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
JP2010514695A (en) 2006-12-21 2010-05-06 プレキシコン，インコーポレーテッド Compounds and methods for kinase regulation and indications therefor
US7820684B2 (en) 2007-03-01 2010-10-26 Supergen, Inc. Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same
US20080234267A1 (en) 2007-03-20 2008-09-25 Karen Elizabeth Lackey Compounds and Methods of Treatment
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
US20080255153A1 (en) 2007-03-28 2008-10-16 Biovitrum Ab (Publ) New compounds
KR101538179B1 (en) 2007-04-03 2015-07-20 어레이 바이오파마 인크. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
CN101720322A (en) 2007-05-04 2010-06-02 Irm责任有限公司 Compounds and compositions as c-kit and pdgfr kinase inhibitors
EP2170827B1 (en) 2007-06-21 2013-08-14 Janssen Pharmaceutica, N.V. Indolin-2-ones and aza-indolin-2-ones
AR067478A1 (en) 2007-07-09 2009-10-14 Astrazeneca Ab COMPOUNDS DERIVED FROM MORPHOLINE PYRIMIDINE
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
RU2474580C2 (en) 2007-07-19 2013-02-10 Шеринг Корпорейшн Heterocyclic amide compounds as protein kinase inhibitors
PL2176231T3 (en) 2007-07-20 2017-04-28 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
JP5632744B2 (en) 2007-08-10 2014-11-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド High affinity human antibodies to human nerve growth factor
AP2010005234A0 (en) 2007-10-16 2010-04-30 Wyeth Llc Thienopyrimidine and pyrazolopyrimidline compoundsand their use as MTOR kinase and P13 kinase inhib itors
BRPI0817812A2 (en) 2007-10-23 2015-04-14 Novartis Ag Use of trkb antibodies to treat respiratory disorders
WO2009060197A1 (en) 2007-11-08 2009-05-14 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyridazines for use as protein kinase inhibitors
CA2706946A1 (en) 2007-11-28 2009-06-04 Schering Corporation 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
EP2215091B1 (en) 2007-12-04 2016-03-30 Nerviano Medical Sciences S.r.l. Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2235062A1 (en) 2008-01-17 2010-10-06 Irm Llc Improved anti-trkb antibodies
US20090227556A1 (en) 2008-01-31 2009-09-10 Eisai R&D Management Co., Ltd. Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives
BRPI0908421C1 (en) 2008-03-03 2021-05-25 Ucb Biopharma Sprl stable solution of a pharmaceutical compound
KR100963051B1 (en) 2008-03-14 2010-06-09 광동제약 주식회사 Oral solution composition shielding bitterness of sulfodehydroabietic aci with small particle size
EP2254886B1 (en) 2008-03-28 2016-05-25 Nerviano Medical Sciences S.r.l. 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US20090275622A1 (en) 2008-04-30 2009-11-05 Prasoona Linga Nizatidine formulations
CA2722418C (en) 2008-05-13 2013-09-17 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (en) 2008-05-19 2009-12-16 Plexxikon Inc PIRROLO [2,3-d] -PYRIMIDINE DERIVATIVES AS KINE MODULATORS
CN102036963B (en) 2008-05-23 2013-08-21 诺瓦提斯公司 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
CN104530052A (en) 2008-06-10 2015-04-22 普莱希科公司 5H-Pyrrolo [2,3-B] pyrazine derivatives for kinase modulation, and indications therefor
CN102105151B (en) 2008-07-29 2013-12-18 内尔维阿诺医学科学有限公司 Use of CDK inhibitor for treatment of glioma
ES2536730T3 (en) 2008-09-19 2015-05-28 Nerviano Medical Sciences S.R.L. 3,4-Dihydro-2H-pyrrolo [1,2-a] pyrazin-1-one derivatives
EP2350075B1 (en) 2008-09-22 2014-03-05 Array Biopharma, Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
PT2350071E (en) 2008-10-22 2014-04-11 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
PE20131197A1 (en) 2008-10-31 2013-11-06 Genentech Inc PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US8912194B2 (en) 2008-11-24 2014-12-16 Nerviano Medical Sciences S.R.L. CDK inhibitor for the treatment of mesothelioma
JO3265B1 (en) 2008-12-09 2018-09-16 Novartis Ag Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease
SI2881402T1 (en) 2009-02-12 2017-12-29 Cell Signaling Technology, Inc. Mutant ROS expression in human liver cancer
WO2010111527A1 (en) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
EP3045457B1 (en) 2009-06-15 2018-05-09 Nerviano Medical Sciences S.r.l. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
EP3305073B1 (en) 2009-12-21 2019-05-15 Samumed, LLC 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US8772279B2 (en) 2010-01-29 2014-07-08 Nerviano Medical Sciences S.R.L. 6,7-dihydroimidazo[1,5-a]pyrazin-8(5H)-one derivatives as protein kinase modulators
EP2536414B1 (en) 2010-02-18 2016-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for preventing cancer metastasis
EP2556172A4 (en) 2010-04-06 2013-10-30 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
TWI510487B (en) 2010-04-21 2015-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
BR122019024201B1 (en) 2010-05-20 2021-08-03 Array Biopharma Inc MACROCYCLIC COMPOUND AS TRK KINASE INHIBITORS, ITS USE, AND PHARMACEUTICAL COMPOSITION
ES2873933T3 (en) 2010-06-09 2021-11-04 Dana Farber Cancer Inst Inc A MEK1 mutation that confers resistance to RAF and MEK inhibitors
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
JP2014005206A (en) 2010-10-22 2014-01-16 Astellas Pharma Inc Arylamino heterocyclic carboxamide compound
KR20190112175A (en) 2010-12-01 2019-10-02 앨더바이오 홀딩스 엘엘씨 Anti-ngf compositions and use thereof
BR112013018515B1 (en) 2011-01-26 2021-06-29 Nerviano Medical Sciences S.R.I TRICYCLICAL PYRROL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE AS KINASE INHIBITORS
JP5925808B2 (en) 2011-01-26 2016-05-25 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Tricyclic derivatives, their preparation and their use as kinase inhibitors
AU2012214762B2 (en) 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
ES2580961T3 (en) 2011-02-24 2016-08-30 Nerviano Medical Sciences S.R.L. Thiazolylphenyl benzenesulfonamido derivatives as Kinase Inhibitors
KR20140014184A (en) 2011-02-25 2014-02-05 아이알엠 엘엘씨 Compounds and compositions as trk inhibitors
JP5976778B2 (en) 2011-04-11 2016-08-24 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Pyrazolyl-pyrimidine derivatives as kinase inhibitors
BR112013026137B1 (en) 2011-04-19 2020-12-01 Nerviano Medical Sciences S.R.L substituted pyrimidinyl-pyrroles as kinase inhibitors
MX342509B (en) 2011-05-12 2016-10-03 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors.
PL2712358T3 (en) 2011-05-13 2017-05-31 Array Biopharma, Inc. Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
JP6016915B2 (en) 2011-07-28 2016-10-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Alkynyl-substituted pyrimidinylpyrroles active as kinase inhibitors
ES2639064T3 (en) 2011-10-07 2017-10-25 Nerviano Medical Sciences S.R.L. 3,4-Dihydropyrrolo [1,2-a] pyrazin-1 (2h) -one derivatives substituted as kinase inhibitors
EP2788350B1 (en) 2011-10-07 2017-12-06 Nerviano Medical Sciences S.r.l. 4-ALKYL SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
WO2013074518A1 (en) 2011-11-14 2013-05-23 Tesaro, Inc. Modulating certain tyrosine kinases
EA025352B1 (en) 2011-12-12 2016-12-30 Др. Редди'С Лабораториз Лтд. SUBSTITUTED PYRAZOLO[1,5-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE (Trk) INHIBITORS
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
ES2605388T3 (en) 2012-04-26 2017-03-14 Ono Pharmaceutical Co., Ltd. Trk inhibitor compound
JP2013226108A (en) 2012-04-27 2013-11-07 Astellas Pharma Inc Method for detecting new ntrk2 activating mutation
CN104395308B (en) 2012-05-23 2016-08-24 内尔维阿诺医学科学有限公司 The preparation method of N-[5-(3,5-diiluoro-benzyl)-1H-indazole-3-base]-4-(4-thyl-piperazin-1-base)-2-(ttetrahydro-pyran-4-base amino)-Benzoylamide
TWI585088B (en) 2012-06-04 2017-06-01 第一三共股份有限公司 Imidazo[1,2-b]pyridazine analogues as kinase inhibitors
RU2643325C2 (en) 2012-06-28 2018-01-31 МакНЕЙЛ-ППС, ИНК. Racecadotril liquid compositions
RU2019102203A (en) 2012-07-11 2019-03-05 Блюпринт Медсинс Корпорейшн FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS
JP6575950B2 (en) 2012-07-24 2019-09-18 ファーマサイクリックス エルエルシー Mutations with resistance to Bruton tyrosine kinase (Btk) inhibitors
EP2689778A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
ES2726833T3 (en) 2012-08-02 2019-10-09 Nerviano Medical Sciences Srl Active substituted pyrroles as kinase inhibitors
JP6223451B2 (en) 2012-08-31 2017-11-01 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Cancer diagnosis and treatment methods
WO2014039971A1 (en) 2012-09-07 2014-03-13 Exelixis, Inc. Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
US20140084039A1 (en) 2012-09-24 2014-03-27 Electro Scientific Industries, Inc. Method and apparatus for separating workpieces
JP2014082984A (en) 2012-10-23 2014-05-12 Astellas Pharma Inc Method for detecting novel ntrk2 activating mutation
AU2013337277B2 (en) * 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel NTRK1 fusion molecules and uses thereof
EP2914622B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
US9604980B2 (en) 2012-11-07 2017-03-28 Nerviano Medical Sciences S.R.L. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
HUE031557T2 (en) 2012-11-13 2017-07-28 Array Biopharma Inc Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
PL2922844T3 (en) 2012-11-13 2018-06-29 Array Biopharma, Inc. N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9546156B2 (en) 2012-11-13 2017-01-17 Array Biopharma Inc. N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
US9790210B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9969694B2 (en) 2012-11-13 2018-05-15 Array Biopharma Inc. N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
CA2877847A1 (en) 2012-11-29 2014-06-05 Yeda Research And Development Co. Ltd. Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors
US9447135B2 (en) 2012-12-14 2016-09-20 University Of Kentucky Research Foundation Semi-synthetic mithramycin derivatives with anti-cancer activity
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
HUE042591T2 (en) 2013-02-19 2019-07-29 Ono Pharmaceutical Co Trk-inhibiting compound
US20160010068A1 (en) 2013-02-22 2016-01-14 Boris C. Bastian Fusion polynucleotides and fusion polypeptides associated with cancer and particularly melanoma and their uses as therapeutic and diagnostic targets
US20140243332A1 (en) 2013-02-27 2014-08-28 Oregon Health & Science University Methods of treating cancers characterized by aberrent ros1 activity
WO2014152965A2 (en) * 2013-03-14 2014-09-25 The Children's Hospital Of Philadelphia Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets
EP2971094B1 (en) 2013-03-15 2021-09-15 Novartis AG Biomarkers associated with brm inhibition
WO2014152777A2 (en) 2013-03-15 2014-09-25 Insight Genetics, Inc. Methods and compositions for the diagnosis and treatment of cancers resistant to ros1 inhibitors
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
US8937071B2 (en) 2013-03-15 2015-01-20 Glaxosmithkline Intellectual Property Development Limited Compounds as rearranged during transfection (RET) inhibitors
WO2014151117A1 (en) 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Identification and use of circulating nucleic acid tumor markers
EP2968551B1 (en) 2013-03-15 2021-05-05 The Trustees of Columbia University in the City of New York Fusion proteins and methods thereof
US10072298B2 (en) 2013-04-17 2018-09-11 Life Technologies Corporation Gene fusions and gene variants associated with cancer
WO2014172046A2 (en) 2013-04-17 2014-10-23 Life Technologies Corporation Gene fusions and gene variants associated with cancer
ES2646019T3 (en) 2013-05-14 2017-12-11 Nerviano Medical Sciences S.R.L. 6-amino-7-deaza-purine derivatives, a process for its preparation and its use as kinase inhibitors
BR112015028845A2 (en) 2013-05-30 2017-07-25 Plexxikon Inc compounds for kinase modulation and indications thereof
TWI610923B (en) 2013-07-11 2018-01-11 Betta Pharmaceuticals Co Ltd Tyrosine protein kinase regulator and application method thereof
JP6534930B2 (en) 2013-07-26 2019-06-26 公益財団法人がん研究会 Detection method of NTRK3 fusion
EP3027654B1 (en) 2013-07-30 2019-09-25 Blueprint Medicines Corporation Pik3c2g fusions
WO2015017533A1 (en) 2013-07-30 2015-02-05 Blueprint Medicines Corporation Ntrk2 fusions
WO2015039006A1 (en) * 2013-09-16 2015-03-19 The General Hospital Corporation Methods of treating cancer
WO2015058129A1 (en) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
LT3057969T (en) 2013-10-17 2018-07-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
KR20160065986A (en) 2013-10-24 2016-06-09 조지타운 유니버시티 Methods and compositions for treating cancer
PL3395814T3 (en) 2013-10-25 2022-08-22 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
JPWO2015064621A1 (en) 2013-10-29 2017-03-09 公益財団法人がん研究会 Novel fusion and detection method thereof
KR102267407B1 (en) * 2014-01-14 2021-06-23 주식회사 엘지화학 Novel NTRK1 fusion gene as colon cancer marker and the uses thereof
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
MY193524A (en) 2014-01-24 2022-10-18 Turning Point Therapeutics Inc Diaryl macrocycles as modulators of protein kinases
US9346788B2 (en) 2014-02-05 2016-05-24 VM Oncology, LLC TrkA receptor tyrosine kinase antagonists and uses thereof
TWI672141B (en) 2014-02-20 2019-09-21 美商醫科泰生技 Molecules for administration to ros1 mutant cancer cells
EP3132056B1 (en) 2014-04-18 2021-11-24 Blueprint Medicines Corporation Pik3ca fusions
US20170044621A1 (en) 2014-04-18 2017-02-16 Blueprint Medicines Corporation Met fusions
CR20160583A (en) 2014-05-15 2017-02-23 Array Biopharma Inc 1 - ((3S, 4R) -4- (3-FLUOROPHENYL) -1- (2-METOXYETHYL) PIRROLIDIN-3-IL) -3- (4-METHYL-3- (2-METHYLPIRIMIDIN-5-IL) - 1-FENIL-1H-PIRAZOL-5-IL) UREA AS INHIBITOR OF TRKA CINASA
WO2015183837A1 (en) 2014-05-27 2015-12-03 Brian Haynes Compositions, methods, and uses related to ntrk2-tert fusions
WO2015183836A1 (en) 2014-05-27 2015-12-03 Brian Haynes Compositions, methods, and uses related to ntrk2-tert fusions
US20170114415A1 (en) 2014-05-30 2017-04-27 The Regents Of The University Of Colorado, A Body Corporate Activating ntrk1 gene fusions predictive of kinase inhibitor therapy
WO2015191667A1 (en) 2014-06-10 2015-12-17 Blueprint Medicines Corporation Pkn1 fusions
WO2015191666A2 (en) 2014-06-10 2015-12-17 Blueprint Medicines Corporation Raf1 fusions
EP3169809B1 (en) 2014-07-17 2020-04-29 Blueprint Medicines Corporation Prkc fusions
US10370723B2 (en) 2014-07-17 2019-08-06 Blueprint Medicines Corporation TERT fusions
WO2016011141A1 (en) 2014-07-17 2016-01-21 Blueprint Medicines Corporation Fgr fusions
CA2955744A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
PL3184519T3 (en) 2014-08-18 2019-09-30 Ono Pharmaceutical Co., Ltd. Acid-addition salt of trk-inhibiting compound
PE20171067A1 (en) 2014-10-14 2017-07-24 Novartis Ag ANTIBODY MOLECULES BINDING AND USES OF PD-L1
KR102562866B1 (en) 2014-11-14 2023-08-04 네르비아노 메디칼 사이언시스 에스.알.엘. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
NZ731909A (en) 2014-11-16 2023-11-24 Array Biopharma Inc Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US20170356052A1 (en) 2014-11-18 2017-12-14 Blueprint Medicines Corporation Prkacb fusions
JP6609631B2 (en) 2014-12-15 2019-11-20 シーエムジー ファーマシューティカル カンパニー，リミテッド Fused ring heteroaryl compounds and uses as TRK inhibitors
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc Shared neoantigens
EP3303382A4 (en) 2015-05-29 2018-12-19 Ignyta, Inc. Compositions and methods for treating patients with rtk mutant cells
KR20180021745A (en) 2015-06-01 2018-03-05 록쏘 온콜로지, 인코포레이티드 How to diagnose and treat cancer
US9782400B2 (en) 2015-06-19 2017-10-10 Macau University Of Science And Technology Oncogenic ROS1 and ALK kinase inhibitor
AU2015101722A4 (en) 2015-06-19 2016-05-19 Macau University Of Science And Technology Oncogenic ros1 and alk kinase inhibitor
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CA2989327A1 (en) 2015-07-02 2017-01-05 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
CA3003153A1 (en) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Point mutations in trk inhibitor-resistant cancer and methods relating to the same
WO2017127835A2 (en) * 2016-01-22 2017-07-27 The Medicines Company Aqueous formulations and methods of preparation and use thereof
TW201733580A (en) 2016-03-11 2017-10-01 小野藥品工業股份有限公司 Treating agent for cancer having TrK inhibitor resistance
SG11201808676RA (en) 2016-04-04 2018-11-29 Loxo Oncology Inc Methods of treating pediatric cancers
CR20180501A (en) 2016-04-04 2019-04-05 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RU2757905C2 (en) 2016-04-19 2021-10-22 Экселиксис, Инк. Method for treating thrice-negative breast cancer
PT3458456T (en) 2016-05-18 2020-12-07 Array Biopharma Inc Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide
WO2017201156A1 (en) 2016-05-18 2017-11-23 Duke University Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab
JOP20190092A1 (en) 2016-10-26 2019-04-25 Array Biopharma Inc PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
CA3080157A1 (en) 2017-10-26 2019-05-02 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers

Also Published As

Publication number Publication date
DOP2018000214A (en) 2019-01-15
CN109414442A (en) 2019-03-01
IL304018A (en) 2023-08-01
CA3019671A1 (en) 2017-10-12
JP2019511575A (en) 2019-04-25
WO2017176751A1 (en) 2017-10-12
AU2017246554B2 (en) 2022-08-18
MX2018012163A (en) 2019-07-08
RU2018137206A (en) 2020-05-12
US20190216814A1 (en) 2019-07-18
KR20180128484A (en) 2018-12-03
RU2018137206A3 (en) 2020-07-28
TN2018000335A1 (en) 2020-01-16
US20170296544A1 (en) 2017-10-19
CU20180125A7 (en) 2019-05-03
TW201801730A (en) 2018-01-16
CR20180501A (en) 2019-04-05
US11484535B2 (en) 2022-11-01
RU2751767C2 (en) 2021-07-16
IL262003A (en) 2018-10-31
SA518400168B1 (en) 2022-11-09
PE20181888A1 (en) 2018-12-11
CL2018002806A1 (en) 2019-03-01
NI201800102A (en) 2019-02-15
EP3439662A1 (en) 2019-02-13
US20200338079A1 (en) 2020-10-29
ECSP18083443A (en) 2019-07-31
CA3019671C (en) 2024-02-20
GEP20227339B (en) 2022-01-25
CN109414442B (en) 2024-03-29
CO2018010761A2 (en) 2018-10-22
AU2017246554A1 (en) 2018-11-01
MA44610A (en) 2019-02-13
TWI746537B (en) 2021-11-21
US10137127B2 (en) 2018-11-27
BR112018070304A2 (en) 2019-01-29
US10668072B2 (en) 2020-06-02
UA125026C2 (en) 2021-12-29
KR102400423B1 (en) 2022-05-19
JP7061602B2 (en) 2022-04-28
CL2019002238A1 (en) 2019-12-27
PH12018502124A1 (en) 2019-08-19

Similar Documents

Publication Publication Date Title
IL262003A (en) Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
RS64698B1 (en) Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
IL290905A (en) Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
IL274066A (en) Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide